A cholesterol-lowering drug now available on the NHS is facing scrutiny after reports that senior government officials bypassed normal approval procedures to fast-track its introduction. The concerns centre on Inclisiran, which could help thousands of patients reduce their risk of heart attacks and strokes, but questions remain about whether proper processes were followed.
Inclisiran works differently from traditional cholesterol tablets like statins. Administered as an injection just twice a year, it targets specific proteins in the liver to reduce "bad" LDL cholesterol in patients at high risk of cardiovascular events. For many patients, this represents a significant convenience over daily medication.
However, The Pharmaceutical Journal has reported "extremely unusual" political influence in the drug's approval process. Rather than following the standard route through the National Institute for Health and Care Excellence (NICE) - which carefully assesses both clinical effectiveness and value for money - the drug appears to have reached NHS patients through direct government intervention.
This departure from established procedures has raised important questions. NICE's rigorous appraisal process exists to ensure the NHS gets the best treatments at fair prices, protecting both patient safety and public funds. When this system is bypassed, it can undermine confidence in how pharmaceutical decisions are made.
The government maintains that its priority is ensuring UK patients benefit from innovative treatments as quickly as possible, with patient safety remaining paramount. Ministers argue that faster access to cutting-edge medicines could save lives and improve outcomes for those at high cardiovascular risk.
However, the Opposition is demanding full transparency about what happened, emphasising that independent scrutiny protects patients and maintains public trust. The controversy highlights broader tensions between the desire for rapid access to new treatments and the need for robust, impartial evaluation of their benefits and costs.